[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614218":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":29,"collaborators":11,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":11,"eligibilityCriteria":38,"healthyVolunteers":35,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":11,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":11,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":11},{"fullName":5,"class":6},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group","EXPERIMENTAL",null,[13],"Drug: Thiotepa",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Thiotepa","The enrolled patients began the pre-treatment on day d-9. The pre-treatment regimen was as follows: Thiotepa 5mg\u002Fkg\u002Fd, from -9d to -8d (2d); Cyclophosphamide: 40 - 50mg\u002Fkg\u002Fd, from -7d to -6d (2d); Busulfan injection: for patients under 55 years old with HCT-CI score of 2 or below, use 3.2mg\u002Fkg\u002Fd from -5d to -3d (3d), for those over 55 years old with HCT-CI score above 2, use 3.2mg\u002Fkg\u002Fd from -5d to -4d (2d);",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Xianming Song, M.D","CONTACT","+86 189 1802 9692","shongxm@139.com",{"name":27,"role":23,"phone":11,"phoneExt":11,"email":28},"Ruiqi Li, M.D","ricky_li13@163.com",{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Xianmin Song, MD","Director","100614218","phase-2-preconditioning-with-a-combination-of-thiotepa-cyclophosphamide-and-busulfan-for-allogeneic-hematopoietic-stem-cell-transplantation-in-the-treatment-of-nkt-cell-lymphoma-100614218",false,"NCT07276737","Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK\u002FT-Cell Lymphoma","Inclusion Criteria:\n\n1\\. Age range: 18-70 years old, gender not restricted. 2. Patients diagnosed with NK\u002FT cell lymphoma through histopathology or flow cytometry, 1) with stage III\u002FIV patients receiving first-line or salvage treatment and achieving remission, 2) stage II patients with relapsed\u002Frefractory disease after salvage treatment achieving remission, 3) patients with NK cell lymphoma\u002Fleukemia receiving first-line or salvage treatment and achieving remission, 4) patients with relapsed\u002Frefractory disease. 3. Patients must have a suitable hematopoietic stem cell donor. 1) The related donor must have at least 5\u002F10 HLA-A, -B, -C, -DQB1, and -DRB1 matching. 2) The unrelated donor must have at least 8\u002F10 HLA-A, -B, -C, -DQB1, and -DRB1 matching. 4. HCT-specific comorbidity index score (HCT-CI) \\\u003C= 2. 5. ECOG: 0-2 points. 6. Liver and kidney functions, as well as heart and lung functions, must meet the following requirements: 1) Serum creatinine \\\u003C= 1.5 × ULN; 2) Cardiac function: Ejection fraction \\>= 50%; 3) Basal oxygen saturation \\> 92%; 4) Total bilirubin \\\u003C= 1.5 × ULN; ALT and AST \\\u003C= 2.0 × ULN; 5) Pulmonary function: DLCO (hemoglobin corrected) \\>= 40% and FEV1 \\>= 50%. 7. Patients must be capable of understanding and willing to participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1\\. Patients allergic to stietap, cyclophosphamide or busulfan or its components. 2. Any unstable systemic diseases: including but not limited to unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 3 months before screening), myocardial infarction (within 3 months before screening), congestive heart failure (NYHA classification ≥ III), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;patients with pulmonary hypertension. 3. Active and uncontrolled infections: hemodynamic instability related to infection, or new symptoms or signs of infection worsening, or new infection lesions found on imaging, persistent fever without exclusion of infection without symptoms or signs; 4. Grade 2 or higher epilepsy, paralysis, aphasia, new cerebral infarction, severe brain trauma, dementia, Parkinson's disease, schizophrenia 5. HIV-infected patients; 6. Patients with active hepatitis B (HBV) or active hepatitis C (HCV) requiring antiviral treatment; 2.patients with a risk of HBV activation, referring to those with positive hepatitis B surface antigen or core antibody but not receiving anti-hepatitis virus treatment; 7. Pregnant or lactating women; 8. Male and female individuals with reproductive capacity who are unwilling to use contraceptive methods during treatment and within 12 months after treatment; 9. Patients whose study investigators assess have other inadvisable inclusion conditions.\n\n\\-","ALL","18 Years","70 Years",{"count":43,"type":44},37,"ESTIMATED","INTERVENTIONAL",[47],"PHASE2","Evaluation of the efficacy and safety of Thiotepa combined with Cyclophosphamide and Busulfan as conditioning regimen before allo-HSCT for the treatment of NK\u002FT cell lymphoma",[50],"NK T-Cell Lymphoma","NOT_YET_RECRUITING","2025-11-29",{"date":54,"type":55},"2025-12-11","ACTUAL",{"date":57,"type":44},"2025-12-30",{"date":59,"type":44},"2029-12-30",{"name":5,"class":6}]